Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
Accession Number
Approved, Investigational
Biologic Classification
Nucleic Acid Based Therapies

Pegaptanib is a polynucleotide aptamer. Pegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability.

  • EYE 001
  • NX 1838
  • NX1838
  • Pegaptanib Octasodium
  • Pegaptanib sodium
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MacugenInjection, solution3.47 mg/1mLIntravitrealBauch & Lomb Incorporated2004-12-17Not applicableUs
MacugenInjection, solution0.3 mgIntravitrealPharma Swiss Ceska Republika S.R.O2006-01-31Not applicableEu
MacugenSolution0.3 mgIntravitrealPfizer Canada Ulc2005-08-262014-09-04Canada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
CAS number



For the treatment of neovascular (wet) age-related macular degeneration.

Associated Conditions

Pegaptanib is a selective vascular endothelial growth factor (VEGF) antagonist. VEGF is a secreted protein that selectively binds and activates its receptors located primarily on the surface of vascular endothelial cells. VEGF induces angiogenesis, and increases vascular permeability and inflammation, all of which are thought to contribute to the progression of the neovascular (wet) form of age-related macular degeneration (AMD), a leading cause of blindness. VEGF has been implicated in blood retinal barrier breakdown and pathological ocular neovascularization.

Mechanism of action

Pegaptanib sodium is a pegylated aptamer, a modified oligonucleotide, which adopts a three- dimensional conformation that enables it to bind to extracellular VEGF with high affinity and selectivity. Pegaptanib sodium binds to the major pathological VEGF isoform, extracellular VEGF165, with high affinity (Kd = 200 pM) and specificity, thereby inhibiting VEGF165 binding to its VEGF receptors. In contrast virtually no binding of the non-pegylated aptamer to VEGF121 or the VEGF -related proteins VEGF-B, VEGF-C and placental growth factor (PlGF) was detected using invitro filter binding assays. Pegaptanib sodium does not bind significantly to VEGF121. In animal models, VEGF164 (the rodent counterpart of human VEGF165) was specifically upregulated in disease. The selective inhibition of VEGF164 with pegaptanib sodium proved as effective at suppressing pathological neovascularization as pan-VEGF inhibition7, however pegaptanib sodium spared the normal vasculature whereas pan-VEGF inhibition did not.

UNeuropilin-1Not AvailableHumans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more

In animals, pegaptanib is slowly absorbed into the systemic circulation from the eye after intravitreous administration.

Volume of distribution

It is distributed into vitreous fluid, retina, aqueous fluid, and kidneys. As well, it has been shown to cross the placenta in mice but whether or not it crosses the placenta in humans is unknown.

Protein binding
Not Available

Based on preclinical data, pegaptanib is metabolized by endo- and exonucleases.

Route of elimination

It is excreted primarily in urine as unchanged drug and also as metabolites. There is no dosage adjustment required for patients with renal impairment although it must be noted that not many studies have looked at patients with a creatinine clearance of 30mL/min.

Half life

In humans, after a 3 mg monocular dose (10 times the recommended dose), the average (± standard deviation) apparent plasma half-life of pegaptanib is 10 (± 4) days.

Not Available

It is not known if pegaptanib is safe in pregnant women or if it is excreted in breast milk. Likewise, no studies have been done in the pediatric population. Most adverse events elated to the drug are ocular however non-ocular adverse events related to the drug or the injection procedure also occurred, among which headaches and rhinorrhoea appeared in more than 1% of patients. Pegaptanib is contraindicated when the patient has an ocular or periocular infection.

Affected organisms
  • Humans and other mammals
Not Available
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
AbacavirAbacavir may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
Abicipar PegolThe therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Pegaptanib.
AcarboseAcarbose may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
AceclofenacAceclofenac may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
AcetaminophenAcetaminophen may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
AcetazolamideAcetazolamide may increase the excretion rate of Pegaptanib which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
AclidiniumPegaptanib may decrease the excretion rate of Aclidinium which could result in a higher serum level.
AcrivastinePegaptanib may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available


General References
  1. Vinores SA: Pegaptanib in the treatment of wet, age-related macular degeneration. Int J Nanomedicine. 2006;1(3):263-8. [PubMed:17717967]
  2. Wylegala E, Teper SJ: [VEGF in age-related macular degeneration. Part II. VEGF inhibitors use in age-related macular degeneration treatment]. Klin Oczna. 2007;109(1-3):97-100. [PubMed:17687925]
  3. Bakri SJ, Pulido JS, McCannel CA, Hodge DO, Diehl N, Hillemeier J: Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye (Lond). 2009 Jan;23(1):181-5. Epub 2007 Aug 10. [PubMed:17693999]
External Links
PubChem Substance
Therapeutic Targets Database
RxList Drug Page Drug Page
ATC Codes
S01LA03 — Pegaptanib
FDA label
Download (99.6 KB)

Clinical Trials

Clinical Trials
1, 2TerminatedTreatmentCystoid Macular Edema2
2CompletedTreatmentDiabetic Macular Edema (DME)1
2CompletedTreatmentHigh Risk Proliferative Diabetic Retinopathy / Type 1 Diabetes Mellitus / Type 2 Diabetes Mellitus1
2CompletedTreatmentMacular Degeneration3
2CompletedTreatmentRetinal Vein Occlusion1
2, 3CompletedTreatmentAge-Related Macular Degeneration (ARMD)2
2, 3CompletedTreatmentMacular Edema Associated With Diabetes Mellitus1
3CompletedTreatmentAnti- VGF Inhibitor / Diabetic Macular Edema (DME) / Retinopathy, Diabetic1
3CompletedTreatmentDiabetic Mellitus / Macular Edema / Retinal Diseases1
3CompletedTreatmentMacular Degeneration1
3CompletedTreatmentMacular Degeneration / Subfoveal Choroidal Neovascularization1
3Unknown StatusTreatmentAge-Related Macular Degeneration (ARMD)1
3WithdrawnTreatmentProliferative Diabetic Retinopathy (PDR)1
4CompletedOtherAge-Related Macular Degeneration (ARMD) / Diabetic Macular Edema (DME) / Retinal Vein Occlusion1
4CompletedTreatmentBranch Retinal Vein Occlusion1
4CompletedTreatmentDiabetic Macular Edema (DME)2
4CompletedTreatmentMacular Degeneration1
4RecruitingTreatmentMacular Diseases1
4TerminatedTreatmentAge Related Macular Degeneration (AMD) / Choroidal Neovascularization (CNV) / Macular Degeneration1
4TerminatedTreatmentAge-Related Macular Degeneration (ARMD)1
4TerminatedTreatmentMacular Degeneration1
4Unknown StatusTreatmentAge-Related Macular Degeneration (AMD)1
4Unknown StatusTreatmentProliferative Diabetic Retinopathy (PDR)1
4WithdrawnNot AvailableNeovascular Age-Related Macular Degeneration1
Not AvailableAvailableNot AvailableDiabetic Macular Edema (DME)1
Not AvailableCompletedNot AvailableAge-Related Macular Degeneration (ARMD) / Macular Degeneration / Neovascular Macular Degeneration1
Not AvailableCompletedNot AvailableMacular Degeneration2
Not AvailableCompletedNot AvailableNeovascular Age-Related Macular Degeneration2
Not AvailableCompletedDiagnosticDiabetic Macular Edema (DME) / Proliferative Diabetic Retinopathy (PDR)1
Not AvailableCompletedTreatmentCystoid Macular Edema / Uveitis1
Not AvailableCompletedTreatmentMacular Degeneration1
Not AvailableRecruitingNot AvailableMacular Diseases1
Not AvailableTerminatedBasic ScienceMacular Degeneration / Regional Blood Flow / Vascular Endothelial Growth Factor1
Not AvailableTerminatedTreatmentHistoplasmosis retinitis / Subfoveal Choroidal Neovascularization1
Not AvailableWithdrawnTreatmentMyopic Choroidal Neovascular Membrane1


Not Available
  • Eyetech Inc.
  • Gilead Sciences Inc.
  • Pfizer Inc.
Dosage forms
Injection, solutionIntravitreal0.3 mg
Injection, solutionIntravitreal3.47 mg/1mL
SolutionIntravitreal0.3 mg
Unit descriptionCostUnit
Macugen 0.3 mg/0.09 ml1194.0USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patent NumberPediatric ExtensionApprovedExpires (estimated)
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more


Experimental Properties
Not Available


Not classified


Pharmacological action
General Function
Vascular endothelial growth factor-activated receptor activity
Specific Function
The membrane-bound isoform 1 is a receptor involved in the development of the cardiovascular system, in angiogenesis, in the formation of certain neuronal circuits and in organogenesis outside the ...
Gene Name
Uniprot ID
Uniprot Name
Molecular Weight
103133.62 Da
  1. Vinores SA: Pegaptanib in the treatment of wet, age-related macular degeneration. Int J Nanomedicine. 2006;1(3):263-8. [PubMed:17717967]

Drug created on October 21, 2007 16:23 / Updated on January 02, 2020 05:34